Introduction {#section1-1533033820937008}
============

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia that is highly curable. The standard treatment for APL, combination of all-trans-retinoic acid (ATRA) and chemotherapy, yields a high rate of complete remission (CR) and can reduce the rate of disseminated intravascular coagulation.^[@bibr1-1533033820937008]^ However, in the subgroup of patients with non-high-risk APL, defined as white blood cell at diagnosis \<10 000/μL,^[@bibr2-1533033820937008]^ arsenic trioxide (ATO) plus ATRA is considered the preferred regimen because studies have demonstrated that patients who received ATRA plus ATO had a higher rate of CR, event-free survival (EFS), and overall survival (OS) as well as a lower cumulative incidence of relapse (CIR) than those who received ATRA plus chemotherapy.^[@bibr3-1533033820937008][@bibr4-1533033820937008]-[@bibr5-1533033820937008]^ In fact, the National Comprehensive Cancer Network guideline recommends ATRA in combination with intravenous ATO as the preferred induction regimen for patients with low-risk APL (and recommends ATRA plus anthracycline-containing chemotherapy as an alternative).^[@bibr6-1533033820937008]^ The major concern for the treatment with ATRA and/or ATO is the development of a life-threatening complication, the APL differentiation syndrome, which can occur during the first days or weeks of treatment.

More recently, there are interests in the use of the oral form of arsenic, named the Realgar-Indigo naturalis formula (RIF). Studies have suggested that the ATRA plus oral RIF regimen has a comparable efficacy to ATRA plus intravenous ATO regimen^[@bibr7-1533033820937008][@bibr8-1533033820937008][@bibr9-1533033820937008]-[@bibr10-1533033820937008]^ but is associated with a lower medical cost and shorter length of hospital stay.^[@bibr7-1533033820937008],[@bibr11-1533033820937008]^ Nonetheless, the data on the efficacy and safety of oral RIF are still relatively limited and, therefore, its role in treatment of APL is still not well-established.^[@bibr6-1533033820937008]^ The current systematic review and meta-analysis was conducted with the aims to identify and summarize the results of all available randomized-controlled studies that compared the efficacy and/or adverse effects of ATRA plus oral RIF regimen versus ATRA plus intravenous ATO regimen in patients with APL.

Materials and Methods {#section2-1533033820937008}
=====================

Data Sources and Searches {#section3-1533033820937008}
-------------------------

The search strategy, which is provided as Supplementary Data 1, involved 2 investigators (NS and WO) independently searching for studies published before October 10, 2018 in the MEDLINE and EMBASE databases. The search terms used were the terms related to arsenic and APL. The references of the included studies were also manually reviewed to identify further eligible studies. This meta-analysis was compiled in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, which is available as Supplementary Data 2.^[@bibr12-1533033820937008]^

Selection Criteria and Data Extraction {#section4-1533033820937008}
--------------------------------------

Studies that are eligible for the meta-analysis must fulfill the following criteria: (1) randomized-controlled studies that compared the efficacy and/or adverse effects of oral versus intravenous arsenic for treatment of APL and (2) reported any of the outcomes of interest, which could be either efficacy (CR, induction mortality, EFS, OS, or CIR) or adverse effects (the rate of differentiation syndrome after induction therapy, the rates of cardiac events, grades 3-4 liver toxicity, grades 3-4 renal toxicity, infection during treatment, bleeding events, or thrombotic events). We excluded nonrandomized studies, observational studies, case series, case report, and review. This process of determination of eligibility was independently performed by the same 2 investigators. If different decisions regarding the eligibility of a particular article were made, the article in question was jointly discussed with the third investigator (NJ) until a consensus decision was reached.

A standard study record form was used by the 2 investigators in order to extract the publication information, methodology, baseline characteristics of participants, and the outcomes of interest from each of the included studies. The 2 investigators performed this process independently, and the extracted data were subsequently cross-checked to ensure accuracy.

Outcome Definitions {#section5-1533033820937008}
-------------------

The CR criteria included a bone marrow blast count of \<5%, the absence of circulating blasts and blasts with Auer rods, the absence of an extramedullary disease, an absolute neutrophil count of ≥1.0 × 10^9^/L, and a platelet count of ≥100 × 10^9^/L.^[@bibr13-1533033820937008]^ The OS rate was defined as the time between induction therapy and the time of death or last follow-up. The EFS rate was defined as the time interval from the diagnosis to the date of primary refractory disease, molecular and hematologic relapse, or death from any cause.^[@bibr13-1533033820937008]^ Relapse was estimated in cases of patients who achieved CR using a cumulative incidence function with respect to the competing risks. Differentiation syndrome consisted of the presence of signs and symptoms of fever, lung infiltrates, respiratory failure, pericardial effusion, pleural effusions, weight increase caused by fluid retention, and acute renal failure. The syndrome commonly occurs within the first 2 weeks after the first induction treatment in patients with APL.^[@bibr14-1533033820937008]^ Cardiac events, grades 3 to 4 liver toxicity, grades 3 to 4 renal toxicity, infection, bleeding events, and thrombotic events were defined according to common terminology criteria for adverse events.^[@bibr15-1533033820937008]^

Quality Assessment of the Included Studies {#section6-1533033820937008}
------------------------------------------

The Jadad quality assessment scale was used to evaluate the quality of the included randomized-controlled studies.^[@bibr16-1533033820937008]^

Statistical Analysis {#section7-1533033820937008}
--------------------

The Mantel-Haenszel method was used to pool the effect estimates and 95% confidence intervals of the included studies together.^[@bibr17-1533033820937008]^ Cochran Q test was calculated and the statistical heterogeneity across the included studies was estimated using the *I* ^2^ statistic. The 4 levels of heterogeneity were as follows: (1) *I* ^2^ value of 0% to 25% indicated insignificant heterogeneity; (2) *I* ^2^ value of 26% to 50% represented low heterogeneity; (3) *I* ^2^ value of 51% to 75% represented moderate heterogeneity; and (4) *I* ^2^ value of 76% to 100% represented high heterogeneity.^[@bibr18-1533033820937008]^ Because of the high likelihood of between-study heterogeneity, random-effects model was utilized rather than fixed-effects model. Statistical significance was defined as *P* values of less than .05. Funnel plot was planned to be created and used for the assessment for publication bias (if there were enough included studies). All statistical analyses were performed using Review Manager 5.3 software from the Cochrane Collaboration (London, United Kingdom).

Results {#section8-1533033820937008}
=======

The search strategy yielded 485 potentially relevant articles (MEDLINE, 65 articles; and EMBASE, 420 articles). Initially, a total of 54 articles were excluded because of duplication. The titles and abstracts of the remaining 431 articles were reviewed which resulted in further exclusion of additional 416 articles for the following reasons: (1) ineligible article type (case report, review, meta-analysis, comments, or editorial); (2) the studies were not performed on patients with APL; (3) the studies did not compare RIF group with ATO group; and (4) the studies did not report the primary outcome of interest. The remaining 15 articles underwent a full-length review, and 11 articles were excluded because of the reasons similar to the first round. Finally, 4 randomized controlled studies met the eligibility criteria and were included in the meta-analysis.^[@bibr7-1533033820937008][@bibr8-1533033820937008][@bibr9-1533033820937008]-[@bibr10-1533033820937008]^ A flow chart of the literature review and selection process is illustrated as [Figure 1](#fig1-1533033820937008){ref-type="fig"}.

![The literature review and selection process.](10.1177_1533033820937008-fig1){#fig1-1533033820937008}

Baseline Patient Characteristics {#section9-1533033820937008}
--------------------------------

A total 482 patients with APL were included (258 received RIF and 224 received ATO). There were more males than females in both groups with the age range of 1 to 60 years. The first 2 studies included both adult and pediatric patients,^[@bibr8-1533033820937008],[@bibr9-1533033820937008]^ while the third one is only based on pediatric^[@bibr7-1533033820937008]^ and the fourth on adult patients.^[@bibr10-1533033820937008]^ Moreover, studies from Wang *et al* ^[@bibr9-1533033820937008]^ and Zhu *et al* ^[@bibr10-1533033820937008]^ were selectively conducted in "non-high risk APL" population, while the others also included "high-risk" patients. According to the Sanz risk classification, 88.8% of the patients in the RIF group and 82.6% of the patients in the ATO group had low-to-intermediate risk APL.^[@bibr19-1533033820937008]^ [Table 1](#table1-1533033820937008){ref-type="table"} demonstrates the baseline characteristics, study period, methodology, and quality assessment of the included studies. [Table 2](#table2-1533033820937008){ref-type="table"} describes the chemotherapy regimens utilized by those studies.

###### 

Characteristics of the Studies Included in the Meta-Analysis.

![](10.1177_1533033820937008-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                       Zhu *et al* ^[@bibr8-1533033820937008]^   Wang *et al* ^[@bibr9-1533033820937008]^       Yang *et al* ^[@bibr7-1533033820937008]^       Zhu *et al* ^[@bibr10-1533033820937008]^                                                                     
  ------------------------------------ ----------------------------------------- ---------------------------------------------- ---------------------------------------------- ------------------------------------------ --------------------- --------------------- --------------------- ---------------------
  Numbers of participants              114                                       117                                            35                                             29                                         40                    42                    69                    36

  Median age in years (range)          33 (15--60)                               39 (15--60)                                    33 (16--59)                                    37 (15--59)                                9.9 (2.1--16)         7.8 (1--13)           34 (24--47)           36 (30--46)

  Gender (M/F)                         61/53                                     65/52                                          22/13                                          18/11                                      22/18                 29/13                 33/36                 16/20

  Disease status                       Newly diagnosed APL                       Newly diagnosed APL                            Newly diagnosed APL                            Newly diagnosed APL                        Newly diagnosed APL   Newly diagnosed APL   Newly diagnosed APL   Newly diagnosed APL

  Median WBC, ×10^9^/L (range)         2.1 (0.3-50.0)                            2.2 (0.3-50.0)                                 1.6 (0.6-9.9)                                  2.2 (0.3-8.1)                              3.6 (1.4-48.0)        5.6 (0.3-227.9)       2.0 (1.1-3.6)         2.1 (1.1-6.2)

  Median platelets, ×10^9^/L (range)   29 (5-333)                                31 (5-164)                                     36 (6-179)                                     40 (8-165)                                 17 (4-226)            23 (4-82)             30 (18-60)            25 (12-48)

  Sanz risk (non-high/high)            93/21                                     92/25                                          35/0                                           29/0                                       32/8                  28/14                 69/0                  36/0

  Study period                         November 2007-July 2011                   November 2007-September 2011                   September 2011-January 2017                    February 2014-August 2015                                                                                    

  Study design                         Randomized controlled study               Randomized controlled study                    Randomized controlled study                    Randomized controlled study                                                                                  

  Jadad quality assessment scale       Three out of 5\                           One out of 5\                                  Two out of 5\                                  Three out of 5\                                                                                              
                                       -No double blind\                         -No double blind\                              -No double blind\                              -No double blind\                                                                                            
                                       -No report of double blind method         -No description of withdrawals and dropouts\   -No description of withdrawals and dropouts\   -No report of double blind method                                                                            
                                                                                 -No report sequence of randomization\          -No report of double blind method                                                                                                                           
                                                                                 -No report of double blind method                                                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ATO, arsenic trioxide; APL, acute promyelocytic leukemia; F, female; M, male; RIF, Realgar-Indigo naturali*s* formula; WBC, white blood cell.

###### 

Treatment Regimens Utilized by the Included Studies.

![](10.1177_1533033820937008-table2)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                 Group   Induction                                   Consolidation                                                              Maintenance
  ------------------------------------------ ------- ------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------
  Zhu *et al* ^[@bibr8-1533033820937008]^    RIF\    -RIF 60 mg/kg/d orally\                     -Homoharringtonine 2 mg/m^2^ for 7 days +AC 100 mg/m^2^ for 5 days then\   -ATRA 25 mg/m^2^ for 15 days for first month\
                                                     -ATRA 25 mg/m^2^/d orally\                  -Daunorubicin 40 mg/m^2^ for 3 days +AC 100 mg/m^2^ for 5 days then\       -RIF 60 mg/kg for 15 days for the second, third month\
                                                     -MA 1.4 mg/m^2^/d for 5 days (high risk)\   -MA 6 mg/m^2^ for 3 days + AC 100 mg/m^2^ for 5 days\                      

                                             ATO     -ATO 0.16 mg/kg/d IV\                       -Homoharringtonine 2 mg/m^2^ for 7 days +AC 100 mg/m^2^ for 5 days then\   -ATRA 25 mg/m^2^ for 15 days for first month\
                                                     -ATRA 25 mg/m^2^/d orally\                  -Daunorubicin 40 mg/m^2^ for 3 days +AC 100 mg/m^2^ for 5 days then\       -ATO 0.16 mg/kg for 15 days for the second and third month\
                                                     -MA 1.4 mg/m^2^/d for 5 days (high risk)    -MA 6 mg/m^2^ for 3 days + AC 100 mg/m^2^ for 5 days\                      

  Wang *et al* ^[@bibr9-1533033820937008]^   RIF\    -RIF 60 mg/kg/d orally\                     -RIF 60 mg/kg/d orally in a 4-week on 4-week off 4 cycles\                 
                                                     -ATRA 25 mg/m^2^/d orally\                  -ATRA 25 mg/m^2^/d orally in a 2-week on 2-week off 7 cycles\              

                                             ATO     -ATO 0.15 mg/kg/d IV\                       -ATO 0.15 mg/kg/d IV\                                                      
                                                     -ATRA 25 mg/m^2^/d orally                   -ATRA 25 mg/m^2^/d orally in a 2-week on 2-week off 7 cycles               

  Yang *et al* ^[@bibr7-1533033820937008]^   RIF\    Risk-adapted protocol:\                     Three courses of consolidation^a^:\                                        Cycle 1:\
                                                     -ATRA 25 mg/m^2^/d orally\                  *Consolidation 1 (28 days):*\                                              -ATRA + RIF 2 wks\
                                                     -MA 10 mg/m^2^, D3 (non-high risk)\         -ATRA 25 mg/m^2^/d orally, D1-D15\                                         -MTX 20 mg/m^2^/wk, 10 wks\
                                                     or MA 7 mg/m^2^, D2-D4 (high risk)\         -MA 10 mg/m^2^, D1-D2\                                                     -6MP 50 mg/m^2^/d, 10 wks\
                                                     -RIF 135 mg/kg/d orally, D5-HCR/HCRp\       *Consolidation 2 (28 days):*\                                              Cycle 2:\
                                                                                                 -AC 1 g/m^2^, D1 and D2 (high risk)\                                       -ATRA 2 weeks\
                                                                                                 -RIF 135 mg/kg/d orally, D1-D15\                                           -MTX + 6MP, 10 weeks\
                                                                                                 *Consolidation 3 (28 days):*\                                              
                                                                                                 -ATRA 25 mg/m^2^/d orally, D1-D15\                                         
                                                                                                 -MA 10 mg/m^2^, D1\                                                        
                                                                                                 -AC 1 g/m^2^, D1-D2 (high risk)\                                           
                                                                                                 -RIF 135 mg/kg/d orally, D1-D15\                                           

                                             ATO     Risk-adapted protocol:\                     Three courses of consolidation^a^:\                                        Cycle 1:\
                                                     -ATRA 25 mg/m^2^/d orally\                  *Consolidation 1 (28 days):*\                                              -ATRA + ATO 2 weeks\
                                                     -MA 10 mg/m^2^, D3 (non-high risk)\         -ATRA 25 mg/m^2^/d orally, D1-D15\                                         -MTX 20 mg/m^2^/wk, 10 weeks\
                                                     or MA 7 mg/m^2^, D2-D4 (high risk)\         -MA 10 mg/m^2^, D1 and D2\                                                 -6MP 50 mg/m^2^/d, 10 weeks\
                                                     -ATO 0.16 mg/kg/d IV, D5-HCR/HCRp           *Consolidation 2 (28 days):*\                                              Cycle 2:\
                                                                                                 -AC 1 g/m^2^, D1-D2 (high risk)\                                           -ATRA 2 weeks\
                                                                                                 -ATO 0.16 mg/kg/d IV, D1-D15\                                              -MTX + 6MP, 10 weeks\
                                                                                                 *Consolidation 3 (28 days):*\                                              
                                                                                                 -ATRA 25 mg/m^2^/d orally, D1-D15\                                         
                                                                                                 -MA 10 mg/m^2^, D1\                                                        
                                                                                                 -AC 1 g/m^2^, D1-2 (high risk)\                                            
                                                                                                 -ATO 0.16 mg/kg/d IV, D1-D15\                                              

  Zhu *et al* ^[@bibr10-1533033820937008]^   RIF\    -RIF 60 mg/kg/d orally\                     -RIF 60 mg/kg/d orally in a 4-week on 4-week off 4 cycles\                 
                                                     -ATRA 25 mg/m^2^/d orally\                  -ATRA 25 mg/m^2^/d orally in a 2-week on 2-week off 7 cycles\              

                                             ATO     -ATO 0.15 mg/kg/d IV\                       -ATO 0.15 mg/kg/d IV\                                                      
                                                     -ATRA 25 mg/m^2^/d orally\                  -ATRA 25 mg/m^2^/d orally in a 2-week on 2-week off 7 cycles               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AC, cytarabine; ATRA, all-trans-retinoic acid; ATO, arsenic trioxide; D, day; HCR, hematologic complete remission; HCRp, HCR with incomplete platelet recovery; IT, intrathecal injection; MA, mitoxantrone; MTX, methotrexate; RIF, Realgar-Indigo naturalis formula; 6MP, 6-mercaptopurine.

^a^ Plus IT AC and dexamethasone D1 of each consolidation.

Treatment Response and Long***-***Term Outcomes {#section10-1533033820937008}
-----------------------------------------------

The chances of achieving CR were numerically higher in the RIF group but the difference was not statistically significant (pooled odds ratio \[OR\]: 4.59, 95% CI: 0.74-28.57, *P* = .10, *I* ^2^ = 0%; [Figure 2A](#fig2-1533033820937008){ref-type="fig"}).^[@bibr7-1533033820937008],[@bibr8-1533033820937008],[@bibr10-1533033820937008]^ The risk of 30-day mortality after the commencement of induction therapy was also lower in the RIF group but the difference was not statistically significant (pooled OR: 0.22, 95% CI: 0.04-1.36, *P* = .10, *I* ^2^ = 0%; [Figure 2B](#fig2-1533033820937008){ref-type="fig"}).^[@bibr8-1533033820937008],[@bibr10-1533033820937008]^ Long-term outcomes (OS, EFS, and CIR) were reported by 3 studies (although the duration of follow-up varied from 2 years to 5 years). The chance of OS was numerically higher in the RIF group than in the ATO group, although the result did not reach statistical significance (pooled OR of 5.48, 95% CI: 0.91-32.86, *P* = .06, *I* ^2^ = 0%; [Figure 3A](#fig3-1533033820937008){ref-type="fig"}).^[@bibr7-1533033820937008],[@bibr8-1533033820937008],[@bibr10-1533033820937008]^ Similar result was observed for the chance of EFS that was numerically higher among patients who received RIF but without statistical significance (pooled OR: 2.87, 95% CI: 0.73-11.33, *P* = .13, *I* ^2^ = 0%; [Figure 3B](#fig3-1533033820937008){ref-type="fig"}).^[@bibr7-1533033820937008],[@bibr8-1533033820937008],[@bibr10-1533033820937008]^ On the other hand, the risk of relapse (CIR) was numerically higher in the RIF group but, again, the difference was not statistically significant (pooled OR: 1.58, 95% CI: 0.20-12.44, *P* = .66, *I* ^2^ = 0%; [Figure 3C](#fig3-1533033820937008){ref-type="fig"}).^[@bibr8-1533033820937008],[@bibr10-1533033820937008]^

![Forest plots of studies that compared the chance of (A) complete remission; and (B) 30-day mortality among patients who received RIF versus ATO. ATO indicates arsenic trioxide; RIF, Realgar-Indigo naturalis formula.](10.1177_1533033820937008-fig2){#fig2-1533033820937008}

![Forest plots of studies that compared the chance of (A) overall survival; (B) event-free survival; and (C) cumulative incidence of relapse among patients who received RIF versus ATO. ATO indicates arsenic trioxide; RIF, Realgar-Indigo naturalis formula.](10.1177_1533033820937008-fig3){#fig3-1533033820937008}

Adverse Effects {#section11-1533033820937008}
---------------

The risk of the development of differentiation syndrome was not significantly different between the groups with the pooled OR comparing the RIF group to the ATO group of 0.65 (95% CI: 0.37-1.13, *P* = .13, *I* ^2^ = 0%; [Figure 4](#fig4-1533033820937008){ref-type="fig"}).^[@bibr7-1533033820937008][@bibr8-1533033820937008][@bibr9-1533033820937008]-[@bibr10-1533033820937008]^ Only the study by Zhu *et al* ^[@bibr10-1533033820937008]^ reported the median time of onset of differentiation syndrome (8 days in the RIF group and 6 days in the ATO group). Similarly, the rates of other adverse effects were not significantly different between the groups which included cardiac complication (pooled OR: 0.44, 95% CI: 0.05-3.68, *P* = .45, *I* ^2^ = 0%; [Figure 5A](#fig5-1533033820937008){ref-type="fig"}),^[@bibr7-1533033820937008],[@bibr10-1533033820937008]^ grades 3 to 4 liver toxicity (pooled OR: 0.78, 95% CI: 0.40-1.53, *P* = .47, *I* ^2^ = 0%; [Figure 5B](#fig5-1533033820937008){ref-type="fig"}),^[@bibr7-1533033820937008],[@bibr8-1533033820937008],[@bibr10-1533033820937008]^ grades 3 to 4 renal toxicity (pooled OR: 0.19, 95% CI: 0.02-1.73, *P* = .14, *I* ^2^ = 0%; [Figure 5C](#fig5-1533033820937008){ref-type="fig"}),^8,10^ infections during treatment (pooled OR: 0.67, 95% CI: 0.44-1.02, *P* = .06, *I* ^2^ = 0%; [Figure 6A](#fig6-1533033820937008){ref-type="fig"}),^7,8,10^ and bleeding (pooled OR: 1.30, 95% CI: 0.60-2.80, *P* = .51, *I* ^2^ = 0%; [Figure 6B](#fig6-1533033820937008){ref-type="fig"}).^7,10^

![Forest plots of studies that compared the risk of differentiation syndrome among patients who received RIF versus ATO. ATO indicates arsenic trioxide; RIF, Realgar-Indigo naturalis formula](10.1177_1533033820937008-fig4){#fig4-1533033820937008}

![Forest plots of studies that compared the risk of (A) cardiac complications; (B) grades 3 to 4 liver toxicity; and (C) grades 3 to 4 renal toxicity among patients who received RIF versus ATO. ATO indicates arsenic trioxide; RIF, Realgar-Indigo naturalis formula.](10.1177_1533033820937008-fig5){#fig5-1533033820937008}

![Forest plots of studies that compared the risk of (A) infections and (B) bleeding events among patients who received RIF versus ATO. ATO indicates arsenic trioxide; RIF, Realgar-Indigo naturalis formula.](10.1177_1533033820937008-fig6){#fig6-1533033820937008}

Evaluation for Publication Bias {#section12-1533033820937008}
-------------------------------

Funnel plot was planned to be used for the evaluation of publication bias. However, the plot was eventually not created because of the small number of the included studies that would critically limit the interpretability of this plot.

Discussion {#section13-1533033820937008}
==========

This is the first systematic review and meta-analysis to summarize all available randomized controlled studies that compared the efficacy and adverse effects of ATRA plus oral RIF regimen versus ATRA plus intravenous ATO regimen for the treatment of APL. The majority of participants in those studies were patients with low-to-intermediate risk APL. The pooled analysis found that clinical outcomes, including CR, 30-day mortality, EFS, and CIR, of patients in both groups were similar, suggesting that efficacy of the 2 regimens was comparable. Similarly, the rate of complications, including differentiation syndrome, cardiac complications, grades 3 to 4 liver toxicity, grades 3 to 4 renal toxicity, and bleeding, was not different between the 2 groups. These results may suggest that ATRA plus oral RIF regimen is, at minimum, not a worse alternative to the standard ATRA plus intravenous ATO regimen for patients with non-high-risk APL. However, the former regimen is associated with a lower cost, shorter hospital stay, and higher quality of life, which could be the appealing reasons for clinicians to use this oral therapy in practice.^[@bibr11-1533033820937008],[@bibr20-1533033820937008]^ There is also a study suggesting the feasibility of switching ATO to RIF treatment in a second stage of induction therapy.^[@bibr21-1533033820937008]^ In addition, RIF is also effective as reinduction and maintenance therapy for patients with relapsed APL.^[@bibr22-1533033820937008]^

The main limitation of the current systematic review and meta-analysis was the limited number of included studies, and one may argue that the nonsignificant results were the function of the limited number of participants rather than the true similarity between the regimens. However, it should be noted that almost all of the results are trending in favor of the ATRA plus oral RIF regimen, including 4.6 times higher chance of achieving CR, 5.5 times higher chance of OS, 2.9 times higher chance of EFS, 35% lower chance of differentiation syndrome, 56% lower chance of cardiac complication, 22% lower chance of liver toxicity, 81% lower chance of renal toxicity, and 33% lower chance of infection. Therefore, it is unlikely that our conclusion that ATRA plus oral RIF regimen is not worse than the standard ATRA plus intravenous ATO regimen would change even if data from additional future randomized controlled studies are available. Another limitation related to the small number of included studies was the inability to perform evaluation for publication bias. Last, approximately 10% of patients included in this meta-analysis had high-risk APL. Since the primary focus of the current study was to study the utility of oral RIF among patients with non-high-risk APL, the inclusion of patients with high-risk APL may have skewed the effect estimates. Unfortunately, subgroup analyses of only patients with non-high-risk APL could not be performed because the included studies did not provide subgroup data on those outcomes of interest.

Conclusion {#section14-1533033820937008}
==========

The current systematic review and meta-analysis study found no significant difference in clinical outcomes among patients with APL who received ATRA plus oral RIF regimen versus those who received standard ATRA plus intravenous ATO regimen. The results may suggest that ATRA plus oral RIF regimen is, at minimum, not a worse alternative.

Supplemental Material {#section15-1533033820937008}
=====================

###### Supplementary_data_1\_APL - Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies
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